Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study
Masanobu Ishii(Kumamoto Health Science University), Naohiro Komura(Kumamoto University), Kenshi Yamanaga(Kumamoto University), Hirofumi Soejima(Kumamoto Health Science University), Yuichiro Arima(Kumamoto University), Kenichi Tsujita(Kumamoto University), Kenji Sakamoto(Kumamoto University), Koichi Sugamura(Jikei University School of Medicine), Yoshiro Onoue(Kumamoto University), Shinsuke Hanatani(Kumamoto University), Daisuke Sueta(Mie University), Tomonori Akasaka, Tomoko Tanaka(Kumamoto University), Seiji Hokimoto(Kumamoto University), Sunao Kojima(Kumamoto University), Koichi Kaikita(Kumamoto University), Takashi Miyazaki, Megumi Yamamuro(IRYO Sosei University), Koichiro Fujisue(Kumamoto University), Satoshi Araki(Kumamoto University), Eiichiro Yamamoto(Mie University), Yasuhiro Izumiya(Kumamoto University), Hiroshige Yamabe(Kumamoto University), Hisao Ogawa(Kumamoto University)
European Heart Journal - Quality of Care and Clinical Outcomes
November 29, 2017
Cited by 74
Related Papers
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|356
Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment: 2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants
|Digestive Endoscopy|2018|261
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
|Circulation|2018|242
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
|European Heart Journal|2019|229